Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

VaccinNate From adjuvants-based vaccines for inflammatory diseases to refined vaccine adjuvants

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 October 2026 to 30 September 2028
Status
Running
EU funding
€194k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101281283

What the project is doing

In the project's own words, from its summary on CORDIS.

T cell–driven inflammatory diseases like multiple sclerosis (MS), are a leading cause of global mortality. This project seeks to harness recent advances in the anti-inflammatory mechanisms of innate immune memory (IIM) and my expertise in vaccinology to develop innovative strategies against these conditions. Innate immune cells can be reprogrammed through trained immunity (TI), enabling them to mount stronger and sustained responses upon re-stimulation.

In vaccinology, adjuvants or adjuvant components (ACs) like β-glucan can trigger such effects. Importantly, myeloid cells such as macrophages can also adopt tolerogenic forms of IIM, known as Trained Tolerogenic Immunity (TTI). These observations suggest that strongest immunosuppressive myeloid-derived suppressor cells (MDSCs) could likewise be reprogrammed to develop TTI. Harnessing this phenotype through ACs presents a novel approach to adjuvant-based vaccine design.

Therefore, building on the premise that ACs such as β-glucan induce robust TI in different innate cells, I hypothesize that selected ACs, or TLR agonists known to promote anti-inflammatory responses, can also elicit specific TTI in MDSCs, which could be leveraged for vaccine development against T cell–driven inflammatory diseases such as MS. To test this, I will characterise the functional, epigenetic and metabolic mechanisms of TTI induced by ACs in MDSCs, building on initial macrophage studies, for subsequently assessing their durability and immunosuppressive capacity using antigen-specific assays to, finally, evaluate their protective potential in a mouse model of MS.

By identifying ACs capable of inducing TTI, this project aims to establish proof-of-concept for novel vaccines that optimise immune responses through precise balance of TI and TTI. These advances will not only contribute to improved vaccine strategies against inflammatory and infectious diseases but also serve as the foundation for my long-term career development in vaccinology.

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI